Patrick J Roberts

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
  2. pmc Clinical use of crizotinib for the treatment of non-small cell lung cancer
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Biologics 7:91-101. 2013
  3. doi request reprint KRAS mutation: should we test for it, and does it matter?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 31:1112-21. 2013
  4. pmc Predicting drug responsiveness in human cancers using genetically engineered mice
    Jerry Usary
    Lineberger Comprehensive Cancer Center, Department of Genetics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 19:4889-99. 2013
  5. pmc Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors
    Austin J Combest
    University of North Carolina Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, 1013 Genetic Medicine Building, CB 7361, Chapel Hill, North Carolina 27599 7361, USA
    Oncologist 17:1303-16. 2012
  6. pmc Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
    Patrick J Roberts
    Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Clin Cancer Res 18:5290-303. 2012
  7. pmc Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Mol Diagn 15:485-97. 2013
  8. pmc Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599, USA
    Clin Cancer Res 16:4864-75. 2010
  9. pmc Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
    Patrick J Roberts
    Department of Genetics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
    J Natl Cancer Inst 104:476-87. 2012

Collaborators

Detail Information

Publications9

  1. doi request reprint Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
    ....
  2. pmc Clinical use of crizotinib for the treatment of non-small cell lung cancer
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Biologics 7:91-101. 2013
    ..e. erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. This review discusses the clinical development and use of crizotinib in NSCLC...
  3. doi request reprint KRAS mutation: should we test for it, and does it matter?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 31:1112-21. 2013
    ..Here we review, in the context of NSCLC, the underlying biology of KRAS mutations, the predictive value of KRAS mutations for therapeutic intervention, and the integration of KRAS mutational testing into our current clinical paradigms...
  4. pmc Predicting drug responsiveness in human cancers using genetically engineered mice
    Jerry Usary
    Lineberger Comprehensive Cancer Center, Department of Genetics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 19:4889-99. 2013
    ..These mouse models offer advantages including precise genetics and an intact microenvironment/immune system...
  5. pmc Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors
    Austin J Combest
    University of North Carolina Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, 1013 Genetic Medicine Building, CB 7361, Chapel Hill, North Carolina 27599 7361, USA
    Oncologist 17:1303-16. 2012
    ..A critical factor influencing the predictability of rodent tumor models is drug PKs, but a comprehensive comparison of plasma and tumor PK parameters among xenograft models, OSTs, GEMMs, and human patients has not been performed...
  6. pmc Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
    Patrick J Roberts
    Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Clin Cancer Res 18:5290-303. 2012
    ..Anticancer drug development is inefficient, but genetically engineered murine models (GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro and xenograft systems...
  7. pmc Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Mol Diagn 15:485-97. 2013
    ..The HEP also exhibited good performance in specimens with low tumor cellularity. Therefore, RT-qPCR gene expression from FFPE specimens can be effectively used to predict lung cancer histology. ..
  8. pmc Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599, USA
    Clin Cancer Res 16:4864-75. 2010
    ..We sought to determine if SCC mRNA expression subtypes exist, are reproducible across multiple patient cohorts, and are clinically relevant...
  9. pmc Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
    Patrick J Roberts
    Department of Genetics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
    J Natl Cancer Inst 104:476-87. 2012
    ....